Positioning of proteasome inhibitors in therapy of solid malignancies Margot S. F. RoetenJacqueline CloosGerrit Jansen Review Article Open access 28 November 2017 Pages: 227 - 243
B7-H3 in tumors: friend or foe for tumor immunity? Gen LiYanchun QuanLijuan Wang Review Article 03 January 2018 Pages: 245 - 253
Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations Xiaojun LiuYingjun JiangWilliam Plunkett Original Article 30 November 2017 Pages: 255 - 267
Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients: results of a multicenter open randomized study Tadahiko ShienHiroyoshi DoiharaTadashi Ikeda Original Article Open access 01 December 2017 Pages: 269 - 275
Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine Lee Cheng PhuaShixu GohEric Chun Yong Chan Original Article 01 December 2017 Pages: 277 - 289
A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin—integration of in vitro results, Phase I and Phase II data and model application for drug–drug interaction potential analysis Nina HankeMichael TeifelThorsten Lehr Original Article 04 December 2017 Pages: 291 - 304
Pharmacokinetics of recombinant asparaginase in children with acute lymphoblastic leukemia Swantje VöllerUwe PichlmeierGeorg Hempel Original Article 05 December 2017 Pages: 305 - 314
Influence of the ABCB1 polymorphisms on the response to Taxane-containing chemotherapy: a systematic review and meta-analysis Qi JiangMeizhen XuXiaoqin Yang Original Article 05 December 2017 Pages: 315 - 323
Model based analysis of the heterogeneity in the tumour size dynamics differentiates vemurafenib, dabrafenib and trametinib in metastatic melanoma Hitesh B. MistryDavid OrrellRaluca Eftimie Original Article Open access 08 December 2017 Pages: 325 - 332
Concordance between the response evaluation criteria in solid tumors version 1.1 and the immune-related response criteria in patients with non-small cell lung cancer treated with nivolumab: a multicenter retrospective cohort study Yuki KataokaKatsuya HiranoHiroshige Yoshioka Original Article 11 December 2017 Pages: 333 - 337
A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting Ichidai TanakaKenji KawadaYoshinori Hasegawa Original Article 12 December 2017 Pages: 339 - 345
Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients L. K. SchochA. AsiamaDouglas E. Gladstone Original Article 13 December 2017 Pages: 347 - 354
Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors Emily ChanE. Gabriela ChioreanHerbert Hurwitz Original Article 13 December 2017 Pages: 355 - 364
CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine Xinna ZhouGuoliang QiaoH. Kim Lyerly Original Article 14 December 2017 Pages: 365 - 372
Immunological hallmarks of cis-DDP-resistant Lewis lung carcinoma cells Olexandr FedorchukYaroslav SusakLarysa Skivka Original Article 30 December 2017 Pages: 373 - 385
A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study) Shunsuke KagawaAtsushi MuraokaToshiyoshi Fujiwara Original Article 30 December 2017 Pages: 387 - 392
A pilot study of daunorubicin-augmented hyper-CVAD induction chemotherapy for adults with acute lymphoblastic leukemia Sung-Yong KimJi Hyun ParkMark Hong Lee Original Article 02 January 2018 Pages: 393 - 398
Prediction of neutrophil reduction using plasma paclitaxel concentration after administration in patients with uterine, ovarian, or cervical cancers in an outpatient clinic Motoaki IshikawaMichiyasu KawaiYoshiyuki Kagawa Original Article 03 January 2018 Pages: 399 - 411
The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer Grant R. WilliamsAllison M. DealHanna K. Sanoff Short Communication 20 November 2017 Pages: 413 - 417
Correction to: A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men Richard MarkusVincent ChowVladimir Hanes Correction Open access 20 November 2017 Pages: 419 - 419
Correction to: Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC) Shang-Chiung ChenMatts KagedalChunze Li Correction 30 November 2017 Pages: 421 - 422
Correction to: Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study Jan de JongPeter HellemansDaniele Ouellet Correction 06 December 2017 Pages: 423 - 423